Physician profile
Neeta Varshney
NPI 1689806606
$3,659.70
in general payments reported to CMS, 2019-2025
25 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $670 · 2021: $281 · 2022: $243 · 2023: $583 · 2024: $719 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $782.29 | 2019-2025 | Hydrus Microstent, Constellation, Eysuvis |
| Rxsight INC | $418.84 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Regeneron Healthcare Solutions, INC. | $329.76 | 2019-2022 | |
| Sight Sciences, INC. | $317.67 | 2019-2025 | Omni Surgical System |
| Eyepoint US, INC. | $237.38 | 2020-2021 | |
| Biotissue Holdings INC. | $234.89 | 2020-2022 | |
| Heidelberg Engineering, INC. | $229.09 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.25 | 2019-2020 | |
| Carl Zeiss Meditec, INC. | $133.75 | 2019-2020 | |
| Ocular Therapeutix, INC. | $115.41 | 2020-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $87.52 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $83.43 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $80.26 | 2023-2025 | Envista Mx60 Iol, Xiidra, Miebo |
| Astellas Pharma US INC | $78.37 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $68.78 | 2023 | Lynparza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $58.05 | 2019-2023 | Tecnis Iol |
| Glaukos Corporation | $53.99 | 2024 | Idose |
| Aerie Pharmaceuticals, INC. | $39.96 | 2019-2021 | |
| Harrow Eye, LLC | $33.40 | 2025 | Vevye |
| Revance Therapeutics, INC. | $26.28 | 2024 | Daxxify |
| Abbvie INC. | $26.12 | 2023 | Lumigan, Alphagan P |
| Allergan, INC. | $24.97 | 2022 | |
| Kala Pharmaceuticals, INC. | $20.81 | 2021 | |
| Optos, INC. | $18.02 | 2020 | |
| Thea Pharma INC. | $16.41 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeta Varshney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.